|
1.
|
|
18 p, 862.2 KB |
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
/
Chari, Ajai (Mount Sinai School of Medicine, USA) ;
Askari, Elham (Hospital Universitario Fundación Jiménez Díaz) ;
Caers, Jo (Centre Hospitalier Universitaire de Liège, Belgium) ;
Costa, Luciano J. (University of Alabama at Birmingham, USA) ;
Hilder, Brandi W. (Janssen Research & Development, Spring House, USA) ;
Krishnan, Amrita (City of Hope Comprehensive Cancer Center, Duarte, USA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Minnema, Monique C. (University Utrecht, Netherlands) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pillarisetti, Kodandaram (Janssen Research & Development, Spring House, USA) ;
Van De Donk, Niels W.C.J. (Vrije Universiteit Amsterdam, Netherlands) ;
Rodríguez-Otero, Paula (Clínica Universidad de Navarra)
What is this summary about? This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. [...]
2023 -  10.2217/fon-2023-0332
Future oncology (London, England), Vol. 19 Núm. 27 (september 2023) , p. 1823-1840
|
|
|
2.
|
|
11 p, 1.9 MB |
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary
/
Barr, Paul M. (University of Rochester Medical Center, USA) ;
Owen, Carolyn (University of Calgary, Canada) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Rabin Medical Center, Petah Tikva, Israel) ;
Burger, Jan A (University of Texas MD Anderson Cancer Center, Houston, USA) ;
Hillmen, Peter (The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK) ;
Dearden, Claire (The Royal Marsden Hospital, London, UK) ;
Grosicki, Sebastian (Silesian Medical University, Katowice, Poland) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Li, Jian Yong (Jiangsu Province Hospital, Nanjing, China) ;
Offner, Fritz (Universitair Ziekenhuis Gent, Belgium) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jermain, Mandy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Hsu, Emily (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Szoke, Anita (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Kipps, Thomas J. (UCSD Moores Cancer Center, San Diego, USA) ;
Ghia, Paolo (Università Vita-Salute San Raffaele &IRCCS Ospedale San Raffaele, Milan, Italy)
What is this summary about? This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022. [...]
2022 - 10.2217/fon-2022-0898
Future oncology (London, England), Vol. 18 Núm. 37 (january 2022)
|
|
|
3.
|
|
8 p, 1.0 MB |
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
/
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Van De Donk, Niels WCJ (Department of Hematology. Amsterdam University Medical Center) ;
Nahi, Hareth (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nooka, Ajay K (Winship Cancer Institute. Emory University) ;
Martin, Thomas (University of California San Francisco) ;
Rosinol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud) ;
Benboubker, Lotfi (Hôpital Bretonneau) ;
Mateos, Maria-Victoria (University Hospital de Salamanca) ;
Popat, Rakesh (University College London Hospitals) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Sidana, Surbhi (Stanford University of Medicine) ;
Delforge, Michele (University of Leuven) ;
Pei, Lixia (Janssen Research & Development) ;
Trancucci, Danielle (Janssen Research & Development) ;
Olyslager, Yunsi (Janssen Research & Development) ;
Uhlar, Clarissa (Janssen Research & Development) ;
Stephenson, Tara (Janssen Research & Development) ;
Rampelbergh, Rian Van (Janssen Research & Development) ;
Banerjee, Arnob (Janssen Research & Development) ;
Kobos, Rachel (Janssen Research & Development) ;
Usmani, Saad Z (Levine Cancer Institute-Atrium Health)
What is this summary about? This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. [...]
2023 - 10.2217/fon-2023-0171
Future oncology (London, England), Vol. 19 Núm. 12 (january 2023) , p. 811-818
|
|
|
4.
|
|
11 p, 3.4 MB |
PIVOT-12 : a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
/
Eggermont, Alexander M. (Princess Máxima Center for Pediatric Oncology & University Medical Center Utrecht) ;
Ascierto, Paolo A. (Istituto Nazionale Tumori IRCCS Fondazione G Pascale) ;
Khushalani, Nikhil I. (H Lee Moffitt Cancer Center & Research Institute) ;
Schadendorf, Dirk (West German Cancer Center at the University Hospital Essen) ;
Boland, Genevieve (Massachusetts General Hospital (Boston)) ;
Weber, Jeffrey (Perlmutter Cancer Center at NYU Langone Health) ;
Lewis, Karl D. (University of Colorado Cancer Center) ;
Johnson, Daniel (Ochsner Medical Center) ;
Rivalland, Gareth (University of Auckland & Auckland City Hospital) ;
Khattak, Adnan (Hollywood Private Hospital. Edith Cowan University) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Gogas, Helen (National & Kapodistrian University of Athens) ;
Long, Georgina V. (Melanoma Institute Australia. University of Sydney. Royal North Shore & Mater Hospitals) ;
Currie, Sue L. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Chien, David (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Tagliaferri, Mary A. (Nektar Therapeutics, San Francisco, CA 94158, USA) ;
Carlino, Matteo S. (Westmead & Blacktown Hospitals & Melanoma Institute Australia. University of Sydney) ;
Diab, Adi (University of Texas MD Anderson Cancer Center)
Bempegaldesleukin (BEMPEG: NKTR-214) is an immunostimulatory IL-2 cytokine prodrug engineered to deliver a controlled, sustained and preferential IL-2 pathway signal. Nivolumab (NIVO), a PD-1 inhibitor, has been shown to prolong survival in patients with advanced melanoma and recurrence-free survival in the adjuvant setting. [...]
2022 - 10.2217/fon-2021-1286
Future oncology (London, England), Vol. 18 Núm. 8 (january 2022) , p. 903-913
|
|
|
5.
|
|
9 p, 1.3 MB |
A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
/
Wu, Yi-Long (Guangdong Lung Cancer Institute. Guangdong Provincial People's Hospital. Guangdong Academy of Medical Sciences) ;
Tsuboi, M. (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ;
John, T. (Department of Medical Oncology. Austin Health) ;
Grohe, C. (Department of Respiratory Diseases. Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, J.W. (David Geffen School of Medicine. University of California) ;
Laktionov, K. (Center of Innovative Technologies and Oncology. N.N. Blokhin Russian Cancer Center. Russian Academy of Medical Sciences) ;
Kim, S.W. (Department of Oncology. Asan Medical Center. University of Ulsan. College of Medicine) ;
Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ;
Vu, H.V. (Department of Thoracic Surgery. Choray Hospital) ;
Lu, S. (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ;
Lee, K.Y. (Precision Medicine. Lung Cancer Center. Konkuk University. Medical Center) ;
Akewanlop, C. (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ;
Yu, C.J. (Department of Internal Medicine. National Taiwan University. Hospital Hsinchu Branch. National Taiwan University. College of Medicine) ;
De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ;
Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto IOV IRCCS) ;
Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Shepherd, F.A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Hospital. University of Toronto) ;
Zeng, L. (Late Oncology Statistics. AstraZeneca) ;
Hodge, R. (Late Oncology Statistics. AstraZeneca) ;
Atasoy, A. (Late Oncology Research and Development. AstraZeneca) ;
Rukazenkov, Y. (Late Oncology Research and Development. AstraZeneca) ;
Herbst, Roy S (Medical Oncology. Yale School of Medicine. Yale Cancer Center)
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. [...]
2021 - 10.2217/fon-2021-0752
Future oncology (London, England), Vol. 17 Núm. 35 (december 2021) , p. 4827-4835
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
